心境障碍中锂盐预防治疗的药物遗传学：儿茶酚-O-甲基转移酶、单胺氧化酶-A和Gβ3基因变异分析

Pharmacogenetics of lithium prophylaxis in mood disorders: analysis of COMT, MAO-A, and Gbeta3 variants.

作者信息

Serretti Alessandro, Lorenzi Cristina, Lilli Roberta, Mandelli Laura, Pirovano Adele, Smeraldi Enrico

机构信息

Department of Psychiatry, Vita-Salute University, Fondazione Centro San Raffaele del Monte Tabor, Milan, Italy.

出版信息

Am J Med Genet. 2002 May 8;114(4):370-9. doi: 10.1002/ajmg.10357.

DOI:10.1002/ajmg.10357

PMID:11992559

Abstract

We studied the possible association between the prophylactic efficacy of lithium in mood disorders and the following gene variants: catechol-O-methyltransferase (COMT) G158A, monoamine oxydase A (MAO-A) 30-bp repeat, G-protein beta 3-subunit (Gbeta3) C825T. A total of 201 subjects affected by bipolar (n = 160) and major depressive (n = 41) disorder were followed prospectively for an average of 59.8 months and were typed for their gene variants using PCR techniques. COMT, MAO-A, and Gbeta3 variants were not associated with lithium outcome, even when possible stratification effects such as sex, polarity, age at onset, duration of lithium treatment, and previous episodes were included in the model. The pathways influenced by those variants are not therefore involved with long-term lithium outcome in our sample.

摘要

我们研究了锂盐在心境障碍中的预防疗效与以下基因变异之间的可能关联

儿茶酚-O-甲基转移酶（COMT）G158A、单胺氧化酶A（MAO-A）30碱基重复序列、G蛋白β3亚基（Gbeta3）C825T。共有201名双相情感障碍（n = 160）和重度抑郁障碍（n = 41）患者接受了平均59.8个月的前瞻性随访，并使用聚合酶链反应（PCR）技术对其基因变异进行分型。即使将性别、极性、起病年龄、锂盐治疗持续时间和既往发作等可能的分层效应纳入模型，COMT、MAO-A和Gbeta3变异与锂盐治疗效果也无关联。因此，在我们的样本中，受这些变异影响的通路与锂盐的长期治疗效果无关。